

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 15814-1US-2
First Inventor Tony ANTAKLY
Title COMPOUNDS WITH ANTI-KS
AND ANTI-HIV ACTIVITY
Express Mail Label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☐ Specification [Total Pages _____]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets _____]
5. Oath or Declaration [Total Sheets _____]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ Paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement [] Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure [] Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☒ Other: Statement Under Section 201.06(a)

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 09/494,500

Prior application information:


Examiner Jeffrey J. Stucker

Art Unit: 1648

For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number: 020988 OR ☐ Correspondence address below

Name	Ogilvy Renault				
Address	Suite 1600				
	1981 McGill College Avenue				
City	Montreal	State		Zip Code	H3A 2Y3
Country	Canada	Telephone	613-780-8661	Fax	613-230-6706
Name (Print/Type)	Paul S. Sharpe		Registration No. (Attorney/Agent)	39,493	
Signature			Date	12/11/2003	

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

22278 U.S. PTO

10/733323



121203

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 465

Complete if Known

Application Number	Not yet assigned:
Filing Date	
First Named Inventor	Tony ANTAKLY
Examiner Name	
Art Unit	
Attorney Docket No.	15814-1US-2

METHOD OF PAYMENT (check all that apply)
☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None
☒ Deposit Account:

Deposit Account Number	19-5113
Deposit Account Name	OGILVY RENAULT

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	385
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$) 385

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Claims		Fee from below		Fee Paid
Independent Claims	7	-20** =	0	X		0
Multiple Dependent Claims	1	-3** =	0	X		0
						0

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$) 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity | Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	80
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	


Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Paul S. Sharpe	Registration No. (Attorney/Agent)	39,493	Telephone	(613) 780-8676
Signature		Date	12/11/2003		

WARNING: Information on this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Direct Dial: (613) 780-8676
Direct Fax: (613) 230-6706
psharpe@ogilvyrenault.com

December 11, 2003

CLASS: 514
SUBCLASS: 002000
GROUP ART UNIT: 1648

Mail Stop PATENT APPLICATION

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
U. S. A.

Sir:

RE: New United States Patent Application
Division of U.S. Patent Application Serial No 09/494,500 filed January 31, 2000
Title: COMPOUNDS WITH ANTI-KS AND ANTI-HIV ACTIVITY
Inventors: Tony ANTAKLY; and Ram M. SAIRAM
Assignee: Altachem Pharma Ltd.
Our File: 15814-1US-2 PSS:LB:lf

Pursuant to Section 201.06 of the *Manual of Patent Examining Procedure*, transmitted herewith for filing is the patent application of:

INVENTORS: Tony ANTAKLY; and
Ram M. SAIRAM

TITLE OF THE INVENTION:
COMPOUNDS WITH ANTI-KS AND ANTI-HIV ACTIVITY

DIVISION OF: United States Patent Application Serial No.: 09/494,500
Filed: January 31, 2000

Status: Allowed on September 8, 2003.

Chain of Title: Recorded as follows:

1. From: Tony ANTAKLY; and Ram M. SAIRAM
To: Université de Montréal

The document was recorded in the United States Patent and Trademark Office at Reel 010538, Frame 0712.

Barristers & Solicitors
Patent & Trade-mark Agents

1981 McGill College Avenue
Suite 1600
Montréal, Quebec
Canada H3A 2Y3

Telephone (514) 845-7126
Fax (514) 288-8389
ogilvyrenault.com

Continuing the practices of
Meighen Demers
Ogilvy Renault
Swabey Ogilvy Renault

Montréal • Ottawa • Québec • Toronto • Vancouver • London (England)

2. From: Université de Montréal

To: Altachem Pharma Ltd.

The document was recorded in the United States Patent and Trademark Office at Reel 010853, Frame 0350.

It is respectfully requested that both assignments described above be recorded against the present application.

I.D.S.: It is respectfully requested that the Information Disclosure Statement filed on May 24, 2000 in connection with Parent Application Serial No. 09/494,500 be transferred over to the present application.

Sequence Listing: It is further respectfully requested that the Compliance Under 37 CFR §1.821-1.825 and Statement Under 1.821(f) filed on January 10, 2001 in connection with Parent Application Serial No. 09/494,500 be transferred over to the present application.

The following documents are enclosed:

- a) Utility Patent Application Transmittal.
- b) Application Data Sheet.
- c) Fee Transmittal Form PTO/SB/17 and Patent Application Fee Determination Record, covering:

Filing Fee (small entity):	\$385.00
Total Number of Claims:	7
Assignment Recordal Fees (2 @ \$40)	<u>\$80.00</u>
TOTAL:	\$465.00

The Commissioner is hereby authorized to charge the above fees and any additional fees which may be required, or credit any overpayment, to our Deposit Account No. 19-5113.

- d) A complete and true copy of the disclosure, claims, abstract, formal drawings (10 Sheets – FIGs. 1-10B), and Declaration from Parent Application Serial No. 09/494,500, together with Statement Under Section 201.06(a).
- e) Preliminary Amendment.

Please note that the address of the agents for the applicant in this matter should be the Montreal address of Ogilvy Renault, Customer No. 020988. Correspondence may be directed to Paul S. Sharpe at the Montreal address of Ogilvy Renault.

Respectfully submitted,

Paul S. Sharpe
Reg. No. 39,493
Agent of Record

Encls.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tony ANTAKLY et al.
Filed: Concurrently herewith
Serial No.: Not yet assigned
Division of Serial No. 09/494,500
Title: COMPOUNDS WITH ANTI-KS AND
ANTI-HIV ACTIVITY
Class-Subclass: 514-002000
Group Art Unit: 1648
Agent of Record: Paul S. Sharpe
Tel. (613) 780-8676
psharpe@ogilvyrenault.com

Mail Stop PATENT APPLICATION


Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
U. S. A.

Sir:

STATEMENT UNDER SECTION 201.06(a)

The undersigned Agent hereby states that the application papers attached hereto are a true and complete copy of Parent Application Serial No. 09/494,500, as filed in the United States Patent and Trademark Office on January 31, 2000.

Date: December 11, 2003

Respectfully submitted,

By: _____
Paul S. Sharpe
Registration No. 39,493
Attorney for Applicant
File No.: 15814-1US-2
PSS:LB:lf

OGILVY RENAULT
1981 McCollege Avenue
Suite 1600
Montreal, QC
Canada H3A 2Y1